Traws Pharma, Inc. logo

Traws Pharma, Inc. (TRAW) Q4 2024 Annual Earnings

TRAW·Reported May 15, 2025·Before market open

Traws Pharma, Inc. reported Q4 2024 revenue of $57.0K (-49.6% YoY), missed analyst consensus of $60.0K by $3.0K. Diluted EPS came in at $2.09, beat the $-8.04 consensus by $10.13.

Revenue
$57.0Kmissed by $3.0K
Consensus: $60.0K
Diluted EPS
$2.09beat by $10.13
Consensus: $-8.04
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001558370-25-004165

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q4 2024 Earnings FAQ

Common questions about Traws Pharma, Inc.'s Q4 2024 earnings report.

Traws Pharma, Inc. (TRAW) reported Q4 2024 earnings on May 15, 2025 before market open.

Traws Pharma, Inc. reported revenue of $57.0K and diluted EPS of $2.09 for Q4 2024.

Revenue missed the consensus estimate of $60.0K by $3.0K. EPS beat the consensus estimate of $-8.04 by $10.13.

Compared to the same quarter a year prior, revenue declined 49.6% from $113.0K a year earlier.

You can read the 10-K periodic report (0001558370-25-004165) directly on SEC EDGAR. The filing index links above go to sec.gov.